Cancer & Disease Research
Cellular programming spurs next-generation cell therapies
Cellular reprogramming of ex vivo cells may offer improvements on first-generation adoptive cell therapies, which have experienced limited clinical success due to complex manufacturing, potential patient rejection, and availability of clinical cell types. Further, in vivo reprogramming may expand on this concept by eliminating the need for manufacture and the risk of immune rejection. Read More
5 ways to improve the biomanufacturing workforce in regenerative medicine
A national survey of regenerative medicine biomanufacturing has revealed gaps in the training of skilled technical workers. The group behind the survey has proposed five steps to improve workforce quality and recently published its recommendations in Stem Cells Translational Medicine. Read More
CAR-NK cells hold promise for solid tumors
A new cancer immunotherapy that leverages the ability of natural killer (NK) cells to discriminate between cancer and normal cells has shown promise in solid tumors. The technology incorporates the cancer-targeting ability of chimeric antigen receptors (CARs), according to data published in iScience on June 25. Read More
Advancing from CAR T-cell therapies to modified NK cell therapies
Chimeric antigen receptor (CAR) T-cell therapies have quickly become promising candidates for the treatment of many cancers. However, other immune cell types, such as natural killer (NK) cells, may be effective for some cancers, such as solid tumors, that are traditionally challenging for CAR T therapies. The science behind this concept is worth examining. Read More
Blackstone, Intellia, Cellex to launch company addressing limitations of cell therapies
Blackstone Life Sciences has committed $250 million toward the launch of a new autologous and allogeneic universal chimeric antigen receptor T-cell therapy company. Also taking part in the launch are Intellia Therapeutics and Cellex Cell Professionals, the parent company of GEMoaB, a clinical-stage cell therapy company. Read More
Personalized cell therapies offer hope for some of the toughest cancers
Complete with a long-term vision of developing a pipeline of oncology therapies that modulate the functional immune system, Sotio of the Czech Republic is breaking into the world of autologous immuno-oncology therapies. The company's goal is to eventually become a prominent European pharmaceutical firm, according to Radek Špíšek, PhD, CEO and founding scientist of Sotio, who spoke with ScienceBoard.net in a recent interview. Read More
Danaher to acquire Aldevron in deal valued at $9.6B
Danaher announced it has signed a deal to buy DNA and messenger RNA manufacturer Aldevron for approximately $9.6 billion. Aldevron will operate as a standalone company in Danaher's Life Sciences business segment and is expected to boost Danaher's activities in genomic medicine. Read More
Lentiviral cell therapies hold promise for monogenic blood disorders
Lentiviral vectors show promise for monogenic blood disorders and the future is bright for these genetically modified cell therapies, according to Dr. Michel Sadelain, PhD, who discussed the topic during the George Stamatoyannopoulos Memorial Lecture at the annual meeting of the American Society of Gene & Cell Therapy. Read More
How one cell transplant platform is poised to tackle complex diseases
Lineage Cell Therapeutics CEO Brian Culley discusses the company's cell therapy technology with ScienceBoard.net. The technology involves the transplantation of differentiated stem cells as part of an off-the-shelf allogeneic cell therapy. Read More
AACR 2021: A case study of T-cell modulation for cancer immunotherapies
During a plenary session at the American Association for Cancer Research (AACR) 2021 virtual meeting held April 9-14, speakers described impressive work that researchers have done to modify and target T cells as a means of treating cancers. Read More
Conferences
CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
Online
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Medical Affairs Strategic Summit (MASS)
September 13-15
New Brunswick, New Jersey United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter